THERAPEUTIC ANTIBODIES: Engineering human antibody derivatives, which specifically recognise and ablate new blood vessels, for the therapy of angiogenesis-related pathologies.

• Unité de recherche: PCRD EU
• Numéro de projet: 00.0604
• Titre du projet anglais: THERAPEUTIC ANTIBODIES: Engineering human antibody derivatives, which specifically recognise and ablate new blood vessels, for the therapy of angiogenesis-related pathologies.

Mots-clé (Anglais)

Angiogenesis; therapeutic antibodies; oncofetal fibronectin; tumot targeting;
Biotechnology; Environmental Protection; Innovation; Technology Transfer; Life Sciences; Medicine; Health; Waste Management

Autre Numéro de projet (Anglais)

EU project number: QLK3-CT-2001-01495

Programme de recherche (Anglais)

EU-programme: 5. Frame Research Programme - 1.1.3 The 'cell factory'

Description succincte (Anglais)

See abstract

Autres indications (Anglais)

Full name of research-institution/enterprise:
ETH Zürich
Institut für Pharmazeutische Wissenschaften
ETH Hönggerberg, HCI G 396.4

Partenaires et organisations internationales (Anglais)

Coordinator: Università degli Studi di Siena (I)

Résumé des résultats (Abstract) (Anglais)

Angiogenesis is a typical process, which underlies cancer, rheumatoid arthritis and the majority of blinding ocular disorders. The ability to selectively target and/or ablate new blood vessels will open diagnostic and therapeutic opportunities. Recently, our network has collaborated for the isolation of antibodies (Ab), which selectively recognise new-forming blood vessels. Two good-quality markers of angiogenesis have been identified. The corresponding high-affinity phage Ab, efficiently target tumoural neovasculature in vivo. We now propose to chemically modify anti- angiogenesis Ab and to test the biomedical potential of their conjugates. In particular, we will use radionuclides and fluorophores to investigate the potential of our labelled Ab for image diagnostics. We will also couple them to drugs, cytokines etc. and evaluate their therapeutic potential in suitable anima l models. We will continue to search for novel markers of angiogenesis.

Références bases de données (Anglais)

Swiss Database: Euro-DB of the
State Secretariat for Education and Research
Hallwylstrasse 4
CH-3003 Berne, Switzerland
Tel. [phone]
Swiss Project-Number: 00.0604